CA4 and cancer: The water-soluble disodium phosphate prodrug of CA-4 (named CA-4P, 1b) has shown promising results in phase II and III clinical trials on advanced cancer based on the vascular shutdown mechanism of action7, thus stimulating significant interest in a variety of CA-4 analogues8.